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Abstract. Curcumin has been shown to exert potential 
antitumor activity in vitro and in vivo involved in multiple 
signaling pathways. However, the application of curcumin 
is still limited because of its poor hydrophilicity and low 
bio-availability. In the present study, we investigated the thera-
peutic effects of a novel and water soluble bis(hydroxymethyl) 
alkanoate curcuminoid derivative, MTH-3, on human breast 
adenocarcinoma MDA-MB-231 cells. This study investigated 
the effect of MTH-3 on cell viability, cell cycle and induction 
of autophagy and apoptosis in MDA-MB-231 cells. After 24-h 
treatment with MTH-3, a concentration-dependent decrease in 
MDA-MB-231 cell viability was observed, and the IC50 value 
was 5.37±1.22 µM. MTH-3 significantly triggered G2/M phase 
arrest and apoptosis in MDA-MB-231 cells. Within a 24-h 
treatment, MTH-3 decreased the CDK1 activity by decreasing 
CDK1 and cyclin B1 protein levels. MTH-3-induced apoptosis 
was further confirmed by morphological assessment and 
Annexin V/PI staining assay. Induction of apoptosis caused 
by MTH-3 was accompanied by an apparent increase of DR3, 
DR5 and FADD and, as well as a marked decrease of Bcl-2 and 
Bcl-xL protein expression. MTH-3 also decreased the protein 
levels of Ero1, PDI, PERK and calnexin, as well as increased 
the expression of IRE1α, CHOP and Bip that consequently led 
to ER stress and MDA-MB-231 cell apoptosis. In addition, 
MTH-3-treated cells were involved in the autophagic process 
and cleavage of LC3B was observed. MTH-3 enhanced the 
protein levels of LC3B, Atg5, Atg7, Atg12, p62 and Beclin-1 in 
MDA-MB-231 cells. Finally, DNA microarray was carried out 
to investigate the level changes of gene expression modulated 
by MTH-3 in MDA-MB-231 cells. Taken together, our results 
suggest that MTH-3 might be a novel therapeutic agent for the 
treatment of triple-negative breast cancer in the near future.
Introduction
Breast cancer is the second leading cause of death in women 
and has approximately 1 million new cases per year world-
wide (1,2). Breast cancer patients develop metastasis eventually 
leading to poor prognosis (3). Triple-negative breast cancer 
(TNBC) accounts for 12-20% of all breast cancer (4). It has 
more aggressive disease progress and worse prognosis (5). 
TNBC characteristics are the lack of expression of estrogen 
receptor (ER), progesterone receptor (PR) and the lack of over-
expression of HER-2 (4,6). TNBC is resistance to anti-hormone 
therapies and HER-2-aiming target therapies (7,8). Treatment 
of TNBC remains a great clinical challenge because of the 
lack of targeting agents and limited therapeutic options (8,9).
Curcumin has been used in traditional Chinese medicine 
for a long time in Taiwan, China and India (10). The phar-
macological effects of curcumin include anti-amyloid (11), 
anti-bacterial (12), anti-depressant (13), anti-inflamma-
tory (14), anti-oxidant (15), anti-diabetes (16) and anticancer 
properties (17,18). In addition, curcumin has been found to 
affect several anticancer signaling pathways such as inhibi-
tion of cancer cell proliferation (19,20) and induction of cell 
cycle arrest (21), apoptosis (22) or autophagy (23). Specifically, 
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the phase II and III clinical trial of curcumin was advocated 
for use in patients with colon and pancreatic cancers (24,25), 
but its low water solubility exerts poor bioavailability and 
primary limiting factors (low efficacy and safety) (26,27). 
To improve these issues, we designed and developed a novel 
bis(hydroxymethyl) alkanoate curcuminoid derivative, MTH-3 
(Fig. 1). In our previous studies, novel bis(hydroxymethyl) 
alkanoate curcuminoid derivatives were shown to exhibit 
antitumor effects on triple-negative breast cancer cells and in 
a xenograft animal experiment (28). The aim of the present 
study was to characterize the property of MTH-3 and to 
clarify the molecular mechanism of MTH-3 in human breast 
adenocarcinoma MDA-MB-231 cells in vitro.
Materials and methods
Chemicals and reagents. MTH-3 was synthesized as previously 
described (28) (patent pending). The purity of MTH-3 is 98.7, 
and its molecular weight is 600.61. Leibovitz's L-15 medium, 
fetal bovine serum (FBS), penicillin-streptomycin, trypsin-
EDTA, Premo Autophagy Sensor LC3B-GFP (BacMam 2.0) 
and 4',6-diamidino-2-phenylindole (DAPI) were purchased 
from Thermo Fisher Scientific (Waltham, MA, USA). The 
antibodies were purchased from Cell Signaling Technology 
(Danvers, MA, USA). All chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated.
Cell culture. The human breast adenocarcinoma cell line 
MDA-MB-231 was purchased from the Bioresource Collection 
and Research Center (BCRC; Hsinchu, Taiwan). Cells were 
cultured in Leibovitz's L-15 medium with 10% FBS and 1% 
penicillin-streptomycin (100 Units/ml penicillin and 100 µg/ml 
streptomycin) in an incubator under 95% air and 5% CO2 at 37˚C.
Cell viability assay and morphologic changes. Cell viability 
was evaluated by the reduction in MTT to yield blue formazan. 
MDA-MB-231 cells (1x104 cells/well) in 96-well plates were 
allowed to attach overnight and then treated with different 
concentrations (1, 3, 5 and 10 µM) of MTH-3 for 24 h. After 
treatments, MTT solution was added to each well (a final 
concentration of 0.5 µg/ml), and then the plates were incubated 
for another 4 h. The medium was removed, blue formazan was 
dissolved in dimethyl sulfoxide (DMSO), and the absorbance 
was read at 570 nm as previously described (29). For trypan 
blue exclusion assay, cells were collected after 1, 3, 5 and 
10 µM of MTH-3 exposure, stained with 0.4% trypan blue 
and then counted on a hemocytometer under a microscope. 
For morphological observation, cells were visualized and 
photographed using a phase-contrast microscope equipped 
with a digital camera (Leica Microsystems GmbH, Wetzlar, 
Germany) as in previous reports (26,30).
Distribution of cell cycle analysis. MDA-MB-231 cells (2x105 
cells/well) in 12-well plates were exposed to 10 µM MTH-3. 
After a 24-h treatment, cells were harvested and fixed gently by 
putting 70% ethanol at 4˚C overnight before being stained with 
PI solution (40 µg/ml PI and 0.1 mg/ml RNase and 0.1% Triton 
X-100) in the dark for 30 min as previously described (31). The 
cells were analyzed for the cell cycle distribution with a flow 
cytometer (FACSCalibur; BD Biosciences, San Jose, CA, USA).
CDK1 kinase assay. CDK1 kinase activity was analyzed 
according to the manufacturer's protocol (CycLex Cdc2-Cyclin 
B Kinase Assay kit; MBL International Corp., Woburn, MA, 
USA). The ability of CDK1 kinase from MDA-MB-231 cell 
extracts prepared from each treatment of 10 µM MTH-3 for 4, 
8, 16 and 24 h was measured as previously described (32,33).
Apoptosis analysis. MDA-MB-231 cells (2x105 cells/well) 
into 12-well plates were incubated in the presence and 
absence of 10 µM MTH-3 for 24 and 48 h. Subsequently, cells 
were harvested and stained with Annexin V and propidium 
iodide (PI) using the Annexin V-FITC apoptosis detection 
kit (BD Biosciences, San Diego, CA, USA) and subjected 
to flow cytometry (BD FACSCalibur; BD Biosciences). 
The percentage of apoptotic cells were quantified with BD 
CellQuest Pro software (BD Biosciences) (34,35).
Cells lysate preparation and western blot analysis. After 
10 µM MTH-3 treatments at indicated intervals of time, 
MDA-MB-231 cells were harvested, washed and suspended 
in the PRO-PREP Protein Extraction Solution (iNtRON 
Biotechnology, Gyeonggi-do, Korea). Protein concentra-
tions were estimated using the Protein Assay kit (Bio-Rad 
Laboratories, Hercules, CA, USA). The samples were resolved 
with SDS-PAGE and transferred to a polyvinylidene difluo-
ride membrane (PVDF) (EMD Millipore, Billerica, MA, 
USA). Each membrane was blocked in 5% non-fat milk in 
Tris-buffered saline with 0.1% Tween-20 for 1 h followed 
by individual incubation with specific primary antibodies 
[cyclin B1 (cat. no. 4138, 1:1,000), CDK1/Cdc2 (cat. no. 9116, 
1:1,000), DR3 (cat. no. 4758, 1:1,000), DR5 (cat. no. 8074, 
1:1,000), FADD (cat. no. 2782, 1:1,000), Bcl-2 (cat. no. 4223, 
1:1,000), Bcl-xL (cat. no. 2764, 1:1,000), Ero1 (cat. no. 3264, 
1:1,000), PDI (cat. no. 3501, 1:1,000), PERK (cat. no. 5683, 
1:1,000), calnexin (cat. no. 2679, 1:1,000), IRE1α (cat. no. 3294, 
1:1,000), CHOP (cat. no. 2895, 1:1,000), Bip (cat. no. 3177, 
1:1,000), Atg5 (cat. no. 12994, 1:1,000), Atg7 (cat. no. 8558, 
1:1,000), Atg12 (cat. no. 4180, 1:1,000), Beclin-1 (cat. no. 3495, 
1:1,000), p62 (cat. no. 88588, 1:1,000), LC3A/B (cat. no. 12741, 
1:1,000) and β-actin (cat. no. 3700, 1:5,000) (Cell Signaling 
Technology, Danvers, MA, USA)] at 4˚C overnight. Each 
membrane was then incubated with anti-rabbit IgG (cat. no. 
7074, 1:10,000) or anti-mouse IgG (cat. no. 7076, 1:10,000) 
horseradish peroxidase (HRP)-linked antibodies (Cell 
Signaling Technology) at room temperature for 1 h. The signal 
was detected with the Immobilon Western Chemiluminescent 
Figure 1. The chemical structures of curcumin (upper panel) and MTH-3 
(bottom panel).
INTERNATIONAL JOURNAL OF ONCOLOGY  52:  67-76,  2018 69
HRP substrate (EMD Millipore) and visualized using the 
LAS 4000 imaging system (Fuji, Tokyo, Japan) as previously 
described (36-38). The quantitative densitometric analysis of 
immunoreactive band was employed by ImageJ bundled with 
64-bit Java 1.6.0_24 program for Windows from the National 
Institutes of Health (NIH; Bethesda, MD, USA).
Immunofluorescence staining. MDA-MB-231 cells (2x106 
cells/dish) were grown on sterile coverslips placed in a 10-cm 
dish. After 10 µM MTH-3 treatment, cells were fixed with 
4% paraformaldehyde and permeabilized with 0.2% Triton 
X-100 in phosphate-buffered saline (PBS). After blocking 
with 2% bovine serum albumin (BSA) in PBS, LC3B and 
p62 were detected using anti-LC3B and anti-p62 antibody 
followed by reaction with FITC- or PE-conjugated secondary 
antibody (BD Biosciences). Coverslips were mounted on glass 
slides with ProLong Gold Antifade reagents (Thermo Fisher 
Scientific) containing DAPI, and fluorescent image was taken 
on a Leica Microsystems TCS SP2 Confocal Spectral micro-
scope as detailed by Lu et al (39).
cDNA microarray analysis. MDA-MB-231 cells were incu-
bated with or without 10 µM MTH-3 for 24 h. After exposure, 
cell pellets were collected, and the total RNA from each 
treatment was purified using the Qiagen RNeasy Mini kit 
(Qiagen, Valencia, CA, USA). RNA purity was determined 
to check the quality at 260/280 nm using a NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific). mRNA was 
amplified and labeled using the GeneChip WT Sense Target 
Labeling and Control Reagents kit (Affymetrix, Santa Clara, 
CA, USA) for expression analysis. The synthesized cDNA 
was labeled with fluorescence and then hybridized for 17 h 
using GeneChip Human Gene 1.0 ST array (Affymetrix) to 
determine microarray hybridization following the manu-
facturer's protocols. The arrays were subsequently washed 
using GeneChip Fluidics Station 450 (Affymetrix), stained 
with streptavidin-phycoerythrin (GeneChip Hybridization, 
Wash and Stain kit; Affymetrix) and scanned on a GeneChip 
Scanner 3000 (Affymetrix). The localized concentrations of 
fluorescent molecules were quantitated and analyzed using 
Expression Console Software (Affymetrix) with default RMA 
parameters as previously described (40). The gene expression 
level of a 2.5-fold change (log2 ratio) was considered a differ-
ence in MTH-3-treated cells in vitro (41,42).
Statistical analysis. Data are presented as the mean ± SD for 
three separate experiment. Differences among the groups were 
considered to be significant at P<0.05 using ANOVA followed 
by the Duncan's test.
Results
MTH-3 inhibits cell proliferation of human breast adenocar-
cinoma MDA-MB-231 cells. At first, the effect of MTH-3 on 
the viability of MDA-MB-231 cells was investigated using the 
MTT and trypan blue exclusion assays. MTH-3 at 1, 3, 5 and 
10 µM significantly reduced the viability of MDA-MB-231 
cells by 98.94±2.26, 89.57±2.07, 69.57±4.13 and 59.6±4.04%, 
respectively (Fig. 2A). Importantly, the cell viability reduction 
after 30 µM MTH-3 challenge is 34.23±3.31%. This effect is in 
a concentration-dependent manner. Data from morphological 
observation revealed that MTH-3 treatment at 10 µM caused 
obvious MDA-MB-231 cell apoptosis and autophagy with 
characteristics, including cytoplasmic membrane blebbing, 
cell shrinkage and autophagic vacuoles (Fig. 2B). Based on 
these findings and gaining effective evidence of cell death, we 
selected MTH-3 at 10 µM for the majority of the experiments 
in MDA-MB-231 cells.
MTH-3 triggers G2/M phase arrest and reduces CDK1 activity 
in MDA-MB-231 cells. To investigate the cell cycle distribu-
tion of treated and untreated MDA-MB-231 cells, cells were 
monitored after 10 µM MTH-3 challenge. Results from flow 
cytometric analysis showed that MTH-3 treatment of MDA-MB-
231 cells significantly increased G2/M phase cell population at 
24 h (Fig. 3A). The effects of MTH-3 on G2/M phase-related 
proteins in MDA-MB-231 cells were investigated. Our results 
showed that MTH-3 effectively down-regulated the levels of 
cyclin B1 and CDK1 (Fig. 3B). We also tested the CDK1 kinase 
activity in MDA-MB-231 cells prior to MTH-3 treatment. 
MTH-3 markedly reduced CDK1 kinase activity at 4, 8, 12 and 
24 h of treatment, respectively (Fig. 3C). Therefore, the finding 
showed that downregulation of CDK1 activity contributed to 
G2/M phase arrest caused by MTH-3 in MDA-MB-231 cells.
MTH-3 elicits cell apoptosis of MDA-MB-231 cells. To further 
explore whether the inhibition of cell viability results from 
the induction of apoptosis in MDA-MB-231 cells, MTH-3-
treated cells were detected with Annexin V/PI double staining 
(Fig. 4). Treatment with 10 µM MTH-3 for 48 h significantly 
increased the population of Annexin V-positive cells (Fig. 4), 
Figure 2. MTH-3 reduces cell viability and affects cell morphology in 
MDA-MB-231 cells. (A) Cells were incubated with or without various 
concentrations (1, 3, 5 and 10 µM) of MTH-3 for 24 h, and the viable cells 
were monitored using an MTT and trypan blue exclusion methods. Data are 
presented as the mean ± SD of three independent experiments. The different 
letters (a-d) show statistically significant differences (P<0.05) in each group 
by the Duncan's test. (B) Cells were examined after with or without 10 µM 
MTH-3 for 24 h to photograph the changes in cell morphology using a phase-
contrast microscope as described in Materials and methods. Scale bar, 10 µm.
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indicating that MTH-3 induced apoptosis in MDA-MB-231 
cells. However, the necrotic cells (Annexin V+/PI+) increased 
rapidly after 48 h of 10 µM MTH-3 exposure.
MTH-3 activates death receptor, mitochondrial and ER 
stress-mediated apoptotic pathways in MDA-MB-231 cells. 
The effects of MTH-3 on apoptosis-related proteins in 
MDA-MB-231 cells were investigated. Our results demon-
strated that MTH-3 upregulated the levels of DR5 and FADD, 
and it downregulated the levels of Bcl-2 and Bcl-xL (Fig. 5A). 
Furthermore, our findings also revealed that MTH-3 markedly 
increased the levels of CHOP and Bip, as well as decreased 
the levels of Ero1, PDI, PERK, calnexin and IRE1α (Fig. 5B). 
These results suggest that MTH-3 induced apoptosis through 
death receptor (extrinsic pathway) and mitochondria (intrinsic 
pathway)-dependent pathways and possibly by modulating ER 
stress mechanism in MDA-MB-231 cells.
MTH-3 stimulates autophagy in MDA-MB-231 cells. 
To confirm if autophagy is involved in the inhibition of 
MDA-MB-231 cell viability, cells with or without MTH-3 
exposure were detected with LC3B and p62 double immuno-
staining. MTH-3 at 10 µM increased the LC3B (FITC; green 
Figure 3. MTH-3 induces G2/M phase arrest of MDA-MB-231 cells. (A) Cells 
were exposed to 10 µM MTH-3 for 24 h. The cell cycle distribution was 
detected using flow cytometric analysis and cell cycle distribution was quanti-
fied. (B) Cells were exposed to 10 µM MTH-3 and then incubated for 0, 4, 8, 16 
and 24 h. The protein levels of cyclin B1, CDK1 and β-actin were determined 
by western blotting. C, control; M, MTH-3 exposure. (C) CDK1 activity was 
examined as described in Materials and methods. Data are presented as the 
mean ± SD of three independent experiments. The different letters (a-b) show 
statistically significant differences (P<0.05) in each group by the Duncan's test.
Figure 4. MTH-3 induces apoptosis of MDA-MB-231 cells. Cells were incu-
bated with 10 µM MTH-3 for 24 and 48 h. Cells were collected and stained 
with Annexin V/propidium iodide (PI) before analysis with flow cytometry. 
The Annexin V-positive cells were counted, and data are presented as the 
mean ± SD of three independent experiments. *P<0.05 indicates statistically 
significant differences by the Duncan's test.
Figure 5. MTH-3 activates death receptor-mediated, mitochondrial and ER 
stress-regulated apoptosis pathways in MDA-MB-231 cells. Cells were exposed 
to 10 µM MTH-3 for 0, 4, 8, 16 and 24 h, and cell lysates were collected for 
western blot analysis. (A) Death receptor-mediated (DR3, DR5 and FADD) and 
mitochondrial (Bcl-2 and Bcl-xL) apoptosis pathways, and (B) ER stress (Ero1, 
PDI, PERK, calnexin, IRE1α, CHOP and Bip) were performed. β-actin served 
as an internal control. C, control; M, MTH-3 exposure.
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color) and p62 (PE; red color) protein expression (Fig. 6), 
indicating that MTH-3 induced autophagy through increasing 
LC3B/p62 signaling in MDA-MB-231 cells.
MTH-3 alters the levels of autophagy-associated proteins 
in MDA-MB-231 cells. Based on the results of autophagy, its 
related signals were further employed by immunoblotting anal-
ysis. MTH-3 treatment induced the levels of Atg5, Atg7, Atg12, 
Beclin-1, p62 and LC3B in a time-dependent manner (Fig. 7). 
These data demonstrated that MTH-3 induced autophagy by 
activating Atg family proteins in MDA-MB-231 cells.
MTH-3 modulates cell death-related gene expression in 
MDA-MB-231 cells by cDNA microarray analysis. After 
treatment with 10 µM MTH-3 for 24 h, cells were collected, 
and cDNA microarray analysis was performed. The analysis 
showed that 97 genes (69 genes, upregulated; 28 genes, down-
regulated) were expressed at least by 2.5-fold compared with 
the untreated control (Table I). The top alteration in gene 
expression scored by the number of pathway networks from 
GeneGo analysis program (Fig. 8). These genes may also be 
involved in cell death and cytotoxic responses in MTH-3-
treated MDA-MB-231 cells.
Discussion
Previous studies have demonstrated the anticancer potential 
of curcumin in regulating cell cycle, autophagy, apoptosis 
and survival, proliferation, angiogenesis, invasion and metas-
tasis (19-23). Guan et al (43) demonstrated that curcumin 
reduced Akt kinase in MDA-MB-231 cells accompanied by a 
decrease in cell proliferation and migration as well as an increase 
in autophagic activity; moreover, AMPK-mediated activation 
Figure 6. MTH-3 induces LC3B and p62 expression of MDA-MB-231 cells. Cells were treated with 10 µM MTH-3 for 24 h. Cells were collected and stained 
with LC3B-FITC antibody (green color) and p62-PE antibody (red color) and analyzed with confocal microscope. DAPI dye (blue color) is for nuclear acid 
(nuclear) staining. Scale bar, 10 µm.
Figure 7. MTH-3 alters the protein levels of autophagy-related proteins in 
MDA-MB-231 cells. Cells were incubated with 10 µM MTH-3 for 4, 8, 16 
and 24 h, and cell lysates were collected for western blot analysis to probe 
autophagic signals (Atg5, Atg7, Atg12, Beclin-1, p62, LC3A and LC3B). 
β-actin was an internal control. C, control; M, MTH-3 exposure.
Figure 8. The possible canonical pathways from MDA-MB-231 cells after 
exposure to MTH-3 by cDNA microarray. Cells were treated with 10 µM 
MTH-3 for 24 h, and then were harvested before total RNA was extracted 
for cDNA microarray assay. The changes in gene expression scored by the 
number of pathways from GeneGo analysis.
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Table I. The >2.5-fold changes in mRNA levels in MDA-MB-231 cells following a 24-h treatment with 10 µM MTH-3 as 
identified using DNA microarray.
ID log2 (ratio) Gene_symbol Description
PH_hs_0049600 6.643856 HSPA6 Heat shock 70 kDa protein 6 (HSP70B')
PH_hs_0006387 6.274261 ZFAND2A zinc finger, AN1-type domain 2A
PH_hs_0004421 5.381376 PPP1R15A Protein phosphatase 1, regulatory subunit 15A
PH_hs_0000305 4.941673 MMP10 Matrix metallopeptidase 10 (stromelysin 2)
PH_hs_0046245 4.763129 RN7SK RNA, 7SK small nuclear
PH_hs_0000076 4.587356 IL12A Interleukin 12A
PH_hs_0027902 4.286664 ABL2 v-abl Abelson murine leukemia viral oncogene homolog 2
PH_hs_0010276 4.189167 DUSP1 Dual specificity phosphatase 1
PH_hs_0031719 4.146525 CCL26 Chemokine (C-C motif) ligand 26
PH_hs_0000156 4.093858 DUSP2 Dual specificity phosphatase 2
PH_hs_0011943 4.063702 HMOX1 Heme oxygenase (decycling) 1
PH_hs_0045501 4.039442 EID3 EP300 interacting inhibitor of differentiation 3
PH_hs_0004561 3.997336 GEM GTP binding protein overexpressed in skeletal muscle
PH_hs_0042334 3.931415 MT4 Metallothionein 4
PH_hs_0048553 3.866096 MYCT1 myc target 1
PH_hs_0000684 3.853854 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9
PH_hs_0035404 3.763571 SAT1 Spermidine/spermine N1-acetyltransferase 1
PH_hs_0000057 3.698185 ATF3 Activating transcription factor 3
PH_hs_0025319 3.562429 C3orf52 Chromosome 3 open reading frame 52
PH_hs_0033101 3.555868 DDIT3 DNA-damage-inducible transcript 3 (CHOP)
PH_hs_0002700 3.513438 OSGIN1 Oxidative stress induced growth inhibitor 1
PH_hs_0037472 3.480422 MALAT1 Metastasis associated lung adenocarcinoma transcript 1
PH_hs_0035765 3.427173 GDF15 Growth differentiation factor 15
PH_hs_0002492 3.366024 SAT1 Spermidine/spermine N1-acetyltransferase 1
PH_hs_0062199 3.356707 AKR1C1|LOC101060798 Aldo-keto reductase family 1, member C1|aldo-keto reductase
   family 1 member C2-like
PH_hs_0000852 3.324182 SESN2 Sestrin 2
PH_hs_0023008 3.242113 FRS2 Fibroblast growth factor receptor substrate 2
PH_hs_0004751 3.219326 MMP1 Matrix metallopeptidase 1 (interstitial collagenase)
PH_hs_0031143 3.213328 VIMP VCP-interacting membrane protein
PH_hs_0025525 3.198476 CLU Clusterin
PH_hs_0024315 3.075314 DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4
PH_hs_0035614 3.062771 RC3H1 Ring finger and CCCH-type domains 1
PH_hs_0027152 3.037995 RMND5A Required for meiotic nuclear division 5 homolog A
   (S. cerevisiae)
PH_hs_0021974 3.010862 DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3
PH_hs_0061784 2.967357 CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1)
PH_hs_0035466 2.962064 AKR1C3|AKR1C1 Aldo-keto reductase family 1, member C3|aldo-keto reductase
   family 1, member C1
PH_hs_0027162 2.960759 SLC3A2 Solute carrier family 3 (activators of dibasic and neutral amino
   acid transport), member 2
PH_hs_0022919 2.960552 CLCF1 Cardiotrophin-like cytokine factor 1
PH_hs_0000255 2.916655 SRGN Serglycin
PH_hs_0024155 2.904033 CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1)
PH_hs_0043719 2.894684 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble)
PH_hs_0045838 2.838192 SLC6A6 Solute carrier family 6 (neurotransmitter transporter, taurine), 
   member 6
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Table I. Continued.
ID log2 (ratio) Gene_symbol Description
PH_hs_0014155 2.836392 HSPA1B Heat shock 70 kDa protein 1B
PH_hs_0044272 2.829317 CLK1 CDC-like kinase 1
PH_hs_0048881 2.809371 FKBP4 FK506 binding protein 4, 59 kDa
PH_hs_0020147 2.803912 CLK1 CDC-like kinase 1
PH_hs_0028987 2.768552 TCF21 Transcription factor 21
PH_hs_0042409 2.76703 DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1
PH_hs_0001262 2.748306 SENP5 SUMO1/sentrin specific peptidase 5
PH_hs_0060828 2.734692 TRIB3 Tribbles homolog 3 (Drosophila)
PH_hs_0023556 2.733421 C21orf91 Chromosome 21 open reading frame 91
PH_hs_0061012 2.731293 ZBTB21 Zinc finger and BTB domain containing 21
PH_hs_0029660 2.695316 AKR1C1 Aldo-keto reductase family 1, member C1|aldo-keto reductase family 1
PH_hs_0037242 2.683231 MALAT1 Metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)
PH_hs_0002812 2.667718 C18orf25 Chromosome 18 open reading frame 25
PH_hs_0027209 2.665362 GADD45B Growth arrest and DNA-damage-inducible, β
PH_hs_0002971 2.664712 ZNF77 Zinc finger protein 77
PH_hs_0003180 2.646292 SMIM13 Small integral membrane protein 13
PH_hs_0000694 2.625719 RND3 Rho family GTPase 3
PH_hs_0023711 2.599232 HSPA5 Heat shock 70 kDa protein 5 
PH_hs_0023894 2.583817 TRIB3 Tribbles homolog 3 (Drosophila)
PH_hs_0060053 2.574976 ZNF121 Zinc finger protein 121
PH_hs_0014119 2.571605 BRF2 BRF2, subunit of RNA polymerase III transcription initiation factor,
   BRF1-like
PH_hs_0033027 2.547837 SIK1 Salt-inducible kinase 1
PH_hs_0024236 2.547678 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2
PH_hs_0042225 2.541029 DUSP5 Dual specificity phosphatase 5
PH_hs_0044921 2.534876 HSPA1A Heat shock 70 kDa protein 1A
PH_hs_0000566 2.528881 SLC25A25 Solute carrier family 25, member 25
PH_hs_0030976 2.516291 NFKBIB Nuclear factor of kappa light polypeptide gene enhancer in
   B-cells inhibitor, β
PH_hs_0014995 -3.653241 METTL7A Methyltransferase like 7A
PH_hs_0023845 -3.269308 BBS2 Bardet-Biedl syndrome 2
PH_hs_0009437 -3.05235 TOP2A Topoisomerase (DNA) II α 170 kDa
PH_hs_0047352 -3.043277 MARCKS Myristoylated alanine-rich protein kinase C substrate
PH_hs_0047965 -2.959225 PHLDA1 Pleckstrin homology-like domain, family A, member 1
PH_hs_0040619 -2.891495 MXD3 MAX dimerization protein 3
PH_hs_0012629 -2.890238 H1F0 H1 histone family, member 0
PH_hs_0004988 -2.878231 LMNB1 Lamin B1
PH_hs_0035609 -2.788184 ETV1 Ets variant 1
PH_hs_0049449 -2.729758 GPR39 G protein-coupled receptor 39
PH_hs_0027843 -2.724437 FAM20C FAmily with sequence similarity 20, member C
PH_hs_0027863 -2.718276 LRRC45 Leucine rich repeat containing 45
PH_hs_0007383 -2.717289 F2R Coagulation factor II (thrombin) receptor
PH_hs_0036878 -2.71449 PIF1 PIF1 5'-to-3' DNA helicase homolog (S. cerevisiae)
PH_hs_0047697 -2.688182 ARF6 ADP-ribosylation factor 6
PH_hs_0048993 -2.677322 NRP1 Neuropilin 1
PH_hs_0031540 -2.66121 GNG2 Guanine nucleotide binding protein (G protein), gamma 2 
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of autophagy contributes to anticancer effects through Akt 
degradation. In the present study, we also checked the growth 
inhibition effect of curcumin on MDA-MB-231 cells. Our data 
indicated that the half maximal inhibitory concentration (IC50) 
value of curcumin on MDA-MB-231 cells is 38.77±3.35 µM. 
Strikingly, the IC50 value of MTH-3 on MDA-MB-231 cells 
is 5.37±1.22 µM (data not shown). Our results demonstrated 
that the MTH-3 had highly cytotoxic effects on MDA-MB-231 
cells. Moreover, we also found that MTH-3 was non-cytotoxic 
on non-tumorigenic epithelial mammary MCF10A cells and 
human skin fibroblast Detroit 551 cells, respectively (data not 
shown). These are only preliminary data and further study is 
needed to validate the findings.
There are no reports regarding that the effects of MTH-3 
on cell cycle arrest, autophagy and apoptosis and associ-
ated gene expression in human breast cancer cells. This 
study is first to demonstrate that MTH-3 induced cytotoxic 
effect on induction of G2/M phase arrest, autophagy and 
apoptosis in human breast adenocarcinoma MDA-MB-231 
cells. The data demonstrated that MTH-3 induced growth 
inhibitory effects through G2/M phase arrest, apoptosis 
and autophagy in MDA-MB-231 cells. Our results showed 
that MTH-3 induced G2/M phase arrest through regulating 
cyclin B1 and CDK1 signaling. G2/M phase progression has 
been reported to regulate CDK1 and CDK2 kinases that are 
activated primarily in association with cyclins A and B (44). 
Furthermore, MTH-3 inhibited the CDK1 activity and the 
protein expression of CDK1 in MDA-MB-231 cells. However, 
neither effect is positively correlated because CDK1 activity 
might be involved in kinase activation rather than CDK1/
cdc2 protein level (32,33). Previous studies also demon-
strated that curcumin inhibited cell proliferation through 
induction of G0/G1 phase arrest of cancer cells (45,46), but 
our finding indicated that MTH-3 induced G2/M phase arrest 
upon different types of cancer cell lines. However, the results 
are in agreement with previous studies to show that curcumin 
inhibited cell proliferation by inducing G2/M phase arrest 
in human glioblastoma U87 cells (47) and in Bcl-2 overex-
pressed MCF-7 cells (48). Further research is required to 
verify the mechanism of MTH-3 action in different breast 
cancer cell lines (such as MCF-7 and MDA-MB-453 cells).
It is well documented that apoptosis plays an important role 
in the maintenance of tissue homeostasis for the elimination of 
excessive cells (49,50). Induction of apoptosis of cancer cells 
by anticancer drugs such as etoposide, cisplatin and paclitaxel 
have been used for treatment of cancer in target cells (51). 
Apoptosis-associated signaling pathways include extrinsic 
(death receptor), intrinsic (mitochondria-dependent) and ER 
stress (unfolded protein response) signals (52,53). Our results 
demonstrated that MTH-3 promoted the protein levels of DR5, 
and FADD and downregulated the levels of Bcl-2 and Bcl-xL 
in MDA-MB-231 cells. MTH-3 also promoted the protein 
levels of CHOP and Bip, and it reduced the levels of Ero1, PDI, 
PERK, calnexin and IRE1α in MDA-MB-231 cells. Our novel 
findings suggest that both extrinsic and intrinsic pathways, 
and ER stress signals were involved in MTH-3-treated cells 
in vitro. This agrees with a previous study reporting that the 
major targets of apoptotic initiation are mediated by dysfunc-
tion of cellular organelles (mitochondria, ER, lysosomes and 
golgi apparatus) (54).
Table I. Continued.
ID log2 (ratio) Gene_symbol Description
PH_hs_0010634 -2.659899 TXNIP|LOC101060503 Thioredoxin interacting protein|thioredoxin-interacting protein-like
PH_hs_0028935 -2.621805 CCDC85B Coiled-coil domain containing 85B
PH_hs_0000866 -2.612763 OMA1 OMA1 zinc metallopeptidase homolog (S. cerevisiae)
PH_hs_0030800 -2.552826 FANCF Fanconi anemia, complementation group F
PH_hs_0025966 -2.55207 CTDSP1 CTD small phosphatase 1
PH_hs_0023862 -2.551096 CBY1 Chibby homolog 1 (Drosophila)
PH_hs_0047571 -2.546813 PDP1 Pyruvate dehyrogenase phosphatase catalytic subunit 1
PH_hs_0028200 -2.537288 CENPI Centromere protein I
PH_hs_0003147 -2.533627 PDGFC Platelet derived growth factor C
PH_hs_0035337 -2.514458 OMA1 OMA1 zinc metallopeptidase homolog (S. cerevisiae)
PH_hs_0038982 -2.502536 LOC100134259 Uncharacterized LOC100134259
Figure 9. The proposed model shows that MTH-3 induces G2/M phase arrest, 
autophagy and apoptotic cell death (death receptor/mitochondrial pathways 
and ER stress) in human breast adenocarcinoma MDA-MB-231 cells.
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Autophagy is another major clearance route for intracel-
lular protein (55). Recently, curcumin can induce autophagy in 
cancer cells (56,57). Our results showed that MTH-3 signifi-
cantly increased protein expression of autophagy markers 
LC3B, Atg complex (Atg5, Atg7 and Atg12) and Beclin-1, as 
well as GFP-LC3 puncta formation, suggesting that LC3B was 
recruited to the autophagosomal membrane during autopha-
gosome formation. Our data strongly suggest that MTH-3 
activated autophagy in MDA-MB-231 cells.
From gene expression profiles by DNA microarray, we 
found that cellular and molecular responses to MTH-3 treat-
ment are multi-faceted and mediated by various regulatory 
pathways in MDA-MB-231 cells. MTH-3 regulated the expres-
sion of important genes in cell cycle, pathways in cancer, 
MAPK signaling, base excision repair, DNA replication, p53 
signaling, homologous recombination, TGF-β signaling, G2/M 
checkpoint, pyrimidine metabolism, Jak-STAT signaling, 
focal adhesion, endocytosis and mismatch repair pathways. 
The gene regulation may be responsible for inhibiting the 
proliferation of MDA-MB-23 cells. Cyclins associate with 
cyclin-dependent protein kinases (CDKs) and CDK inhibitor 
(CKI) can control the procedure of cell cycle to arrest the cell 
cycle and inhibit the cell growth of cancer cells (44,58). Our 
results from gene expression profiles indicated that MTH-3 
changed the expression of cyclin and cyclin-dependent kinase 
inhibitor gene CDKN1A, suggesting a change in cyclin, cyclin-
dependent kinase inhibitors which could finally lead to cell 
cycle G2/M phase arrest.
Heme oxygenase-1 (HO-1) has been implicated in cellular 
defense against oxidative stress and has anti-inflammation 
function (59,60). A recent study has demonstrated that curcumin 
inhibits appoptosin-induced apoptosis by upregulating HO-1 
expression in SH-SY5Y cells (61). Curcumin-induced HO-1 
expression also prevents H2O2-induced cell death in wild-
type and HO-2 knockout adipose-derived mesenchymal stem 
cells (62). In this study of the gene expression profiles, MTH-3 
upregulated the expression of heme oxygenase 1 (HMOX1) 
gene, suggesting that MTH-3 might have anti-inflammation 
and cell protection function.
In conclusion, the molecular signaling pathways are 
summarized in Fig. 9. This study is the first report to provide 
an approach regarding the bis(hydroxymethyl) alkanoate 
curcuminoid derivative, MTH-3 tends to inhibit human 
breast adenocarcinoma MDA-MB-231 cells. Based on the 
presented novel findings, the efficacy of MTH-3 might be 
sufficient to further investigate the potential of breast cancer 
treatment.
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